Innovacell Taps Shareholders to Raise $10.7M for Phase III

LONDON – Innovacell Biotechnologie AG raised €8.3 million (US$10.7 million) from existing shareholders as it began a Phase III study of ICES13, its autologous cell therapy for the treatment of stress urinary incontinence.